Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Arabinoxylan-Oligosaccharides Compared to Other Prebiotics in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier:
NCT00853034
First received: February 25, 2009
Last updated: February 26, 2009
Last verified: February 2009
  Purpose

The purpose of the study is to evaluate the effects of arabinoxylan-oligosaccharides (AXOS) on the colonic metabolism and microbial composition, and to compare these effects with the reference prebiotic fructo-oligosaccharide enriched inulin.


Condition Intervention Phase
Healthy
Dietary Supplement: FOS-IN
Dietary Supplement: AXOS
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Effects of Arabinoxylan-Oligosaccharides on Colonic Metabolism and Microbial Composition Compared to Other Prebiotics in Healthy Subjects

Further study details as provided by Katholieke Universiteit Leuven:

Enrollment: 20
Study Start Date: October 2006
Study Completion Date: September 2007
Arms Assigned Interventions
Active Comparator: FOS-IN
prebiotic fructo-oligosaccharide enriched inulin
Dietary Supplement: FOS-IN

prebiotic fructo-oligosaccharide enriched inulin

intake period: 2 weeks, 1.25 or 2.50g every morning and evening

Other Name: Synergy1, Orafti, Tienen
Experimental: AXOS
arabinoxylan-oligosaccharides (AXOS)
Dietary Supplement: AXOS

arabinoxylan-oligosaccharides (AXOS)

intake period: 2 weeks, 1.25 or 2.50g every morning and evening


  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy
  • 18-45 years
  • regular eating pattern

Exclusion Criteria:

  • gastrointestinal complaints
  • antibiotic intake
  • medication influencing gut transit or microbiota
  • abdominal surgery
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00853034

Locations
Belgium
Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, Belgium, 3000
Sponsors and Collaborators
Katholieke Universiteit Leuven
Investigators
Study Director: Kristin Verbeke, PhD Katholieke Universiteit Leuven
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00853034     History of Changes
Other Study ID Numbers: AXOS 001
Study First Received: February 25, 2009
Last Updated: February 26, 2009
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by Katholieke Universiteit Leuven:
gastrointestinal effects
prebiotic

ClinicalTrials.gov processed this record on November 27, 2014